key: cord-0809197-k4mln5vk
authors: Augusto, Danillo G.; Hollenbach, Jill A.
title: HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection
date: 2022-03-25
journal: Curr Opin Immunol
DOI: 10.1016/j.coi.2022.102178
sha: 1b4cf92a4f9619cd2e749ee8078bf408965576a6
doc_id: 809197
cord_uid: k4mln5vk

The extraordinary variation of the human leukocyte antigen (HLA) molecules is critical for diversifying antigen presentation to T cells. Coupled with the rise of novel strains and rapidly evolving immune evasion SARS-CoV-2 proteins, HLA-mediated immunity in COVID-19 is critically important but far from being fully understood. A growing number of studies have found association of HLA variants with different COVID-19 outcomes and that HLA genotypes associate with differential immune responses against SARS-CoV-2. Prediction studies have shown that mutations in multiple viral strains, most concentrated in the Spike protein, affect the affinity between these mutant peptides and HLA molecules. Understanding the impact of this variation on T-cell responses is critical for comprehending immunogenic mechanisms in both natural immunity and vaccine development.

Since nearly the start of the global COVID-19 pandemic, there has been an intensive effort to deduce the genetic and immune features that may underlie variation in susceptibility to infection with SARS-CoV-2, as well as disease outcomes in COVID-19. Most COVID-19 patients are either asymptomatic or experience relatively mild symptoms, including fever and cough, but some individuals develop severe pneumonia; a subset of those individuals will progress to develop acute respiratory distress syndrome (ARDS). Acutely ill patients may further develop shock and multiple organ failure [1] . Many specific demographic, medical, and behavioral risk factors have been identified as contributory to more severe disease and poor outcomes.

Advanced age, comorbidities such as diabetes and hypertension, smoking history, and African American ancestry have all been associated with increased morbidity and mortality in COVID- 19 , for example [2] Infection with SARS-CoV-2 activates both innate and adaptive immune responses. The adaptive immune response is a critical component of protection from viral pathogens. CD4 T cells promote virus-specific antibodies through their action on T-dependent B cells, while CD8 T cells' cytotoxic capacity may kill virally infected cells. T cell responses to SARS-CoV-2 are crucial factors for recognizing and killing infected cells [3] . At the same time, T cells from patients with severe disease have been shown to have phenotypic characteristics associated with differential cytokine secretion, and that these differences are antigen dependent [4] . Because of their pivotal J o u r n a l P r e -p r o o f role in antigen presentation to T cells, the genes encoding the human leukocyte antigen (HLA) molecules have been a primary focus in genetic association studies across a multitude of infectious and immune-mediated disease. We and others have been actively engaged in studies to pinpoint specific HLA alleles associated with risk for SARS-CoV-2 infection and/or specific COVID-19 disease outcomes, and more recently, vaccine response. Proceeding in tandem, numerous efforts have sought to identify viral antigens presented either by specific HLA or broadly across allotypes, and in particular, those acting as T cell epitopes. By synthesizing information pertinent to antigen presentation and T cell reactivity with HLA genetic associations, we are beginning to develop a more comprehensive picture of the immune mechanisms underpinning differential host response to SARS-CoV-2 exposure and infection.

The HLA genes are located within the human major histocompatibility complex (MHC), located on the short arm of chromosome 6 (p21.3). HLA molecules are critical components of the adaptive immune system, which mediates the specific destruction of infected cells and the production of antibodies. Classical HLA class I molecules (HLA-A, HLA-B, and HLA-C) are expressed on all nucleated cells and contain two non-covalently bound polypeptide chains. The polymorphic alpha chain is encoded by the HLA gene within the MHC region, while the gene for the non-polymorphic beta-2 microglobulin chain is located on chromosome 15. HLA class I molecules present endogenous peptides, including those derived from intracellular pathogens such as viruses. Foreign peptides presented on class I antigens are recognized by cytotoxic CD8 T lymphocytes [5] . Classical HLA class II molecules (HLA-DR, HLA-DQ, and HLA-DP) are heterodimers composed of an alpha and beta chain encoded by genes within the MHC and present peptides generated in endosomes from protein sources both inside and outside the presenting cell to CD4 T lymphocytes [6] . In contrast to the constitutive expression of class I molecules, the expression of class II molecules is limited to cells of specialized function in immunity, collectively known as professional antigen-presenting cells, including primarily dendritic cells, macrophages, and mature B lymphocytes. In addition, HLA class II are highly expressed on the surface of epithelial cells in both the lung and intestine [7] , which is potentially relevant in the context of SARS-CoV-2 infection.

The HLA genes are the most polymorphic region of the human genome [8] . More than 30,000 HLA alleles have been identified to date, which encode more than 18,000 unique proteins (allotypes) [9] . The majority of nucleotide substitutions in HLA alleles are concentrated in the J o u r n a l P r e -p r o o f exons encoding the peptide-binding groove and the region of interaction with T-cell receptors, and, importantly, the most polymorphic positions are those that affect peptide binding [10] . This remarkable variation in the peptide binding groove affects its geometry, charge distribution, and hydrophobicity, determining interaction with individual peptides. Diverse HLA molecules may exhibit distinctive peptide-binding repertoires, while individuals with different HLA genotypes may exhibit a differential ability to present specific peptides and elicit immune responses. These variable elements in antigen presentation underlie the many known HLA associations with human disease [11] Association of HLA polymorphism with COVID-19 disease course HLA class I and class II alleles have been previously associated with the severe acute respiratory syndrome caused by SARS-CoV [12] . The most robust genetic association studies to-date for SARS-CoV-2 infection have primarily focused on disease outcomes, given the inherent difficulty in assessing infection risk and controlling for exposure. In many cases, these studies have specifically examined severe outcomes in disease (e.g., need for mechanical ventilation or death). Thus far, numerous HLA class I and II alleles have been associated with disease outcomes, but without clear consensus. Indeed, some large studies, either in the context of genome wide-association studies (GWAS) [13] or large HLA databases [14] , have failed to show a significant influence of HLA genotype on disease.

Nevertheless, some interesting results have emerged and are summarized in Table 1 . For example, HLA-C*04:01 was found to be associated with severe clinical course of COVID-19 in European patients, with carriers of this allele having twice the risk of requiring mechanical ventilation [15] . In contrast, a different class I allele, HLA-A*11:01, was associated with severe disease in one Japanese cohort [16] , while a class II allele, HLA-DRB1*09:01, was identified in another [17] . Of note, HLA-A*11:01 was also associated with severe outcome in a Chinese cohort [18] , further supporting that observation. In less severe disease, asymptomatic infection is particularly interesting, as it suggests the capacity for early viral clearance. Langton et al. [19] found a significant association of HLA-DRB1*04:01 in asymptomatic patients with European ancestry relative to those with severe disease. Interestingly, this allele was recently associated with milder disease in an Iranian patient population [20] . Likewise, in our own work, we identified HLA-B*15:01, a class I allele in strong linkage disequilibrium with HLA-DRB1*04:01, as strongly associated with asymptomatic infection in patients with European ancestry [21] . Discrepancies across studies may be attributed to differences in the definition of disease phenotypes, study J o u r n a l P r e -p r o o f population, and often limited sample sizes. Thus, while the results are mixed, some consistent patterns are beginning to emerge with respect to HLA associations in SARS-CoV-2 infection, and may serve as a basis for interpreting studies related to antigen presentation.

A series of early in silico analyses pointed to HLA as relevant molecules for SARS-CoV-2 risk and important targets for vaccine development [25] [26] [27] [28] . Interestingly, it was shown that HLA-B*46:01 has a low predicted binding of peptides for SARS-CoV-2. This observation suggests that individuals expressing this molecule may be more vulnerable to COVID-19 [27] , which corroborated previous results showing HLA-B*46:01 association with SARS risk [29] . In contrast, HLA-15:03 was predicted to protect against COVID-19 by having the greatest ability to present highly conserved SARS-CoV-2 peptides to T cells [27] .

Most protein-level mutations in all recently discovered SARS-CoV-2 strains concentrate in the Spike protein (Figure 1) , the main target for COVID-19 vaccines [30, 31] due to its high antigenicity and capacity to induce robust immune responses [32, 33] . Not surprisingly, variation in SARS-CoV-2 strains can also affect HLA binding and antigen presentation, whereby a given HLA allotype that may efficiently present a wild-type peptide has differential capacity to present a mutant strain (Figure 2) . NetMHCpan-4.1 and NetMHCIIpan-4.0 are tools that use tailored machine learning strategies to integrate predictors trained on binding affinity data and mass spectrometry experiments [34] . Leveraging these tools, Nersisyan et al. have created a tool that comprehensively tracks how SARS-CoV-2 mutations are predicted to affect HLA binding [35] . By curating their data, we can observe distinct patterns of HLA affinity to different strains ( Figure   3A ). Delta, highly contagious [36] , and Omicron, heavily mutated and associated with increased risk of reinfection [37, 38] , are the two most prevalent SARS-CoV-2 variant strains to date.

Interestingly, Omicron is the variant that encodes the largest number of epitopes predicted to strongly bind both HLA class I and class II (Figure 3B) , with even more pronounced differences for the Spike protein ( Figure 3C) . Although predictions do not necessarily correlate with T-cell responses, these data allow us to speculate that Omicron mutations, particularly in the spike protein, may not have a detrimental overall effect on HLA mediated T-cell immunity. HLA class II accounts for more than 90% of the stronger binding predictions for all SARS-CoV-2 variants.

Among HLA class I, HLA-A accounts for most of the stronger binding predictions, while HLA-B has the most significant number of weak binding predictions (Figure 3D) . In HLA class II, HLA-DQ is predicted to bind strongly to a small number of peptides and accounts for most of the Table 1 ). On the other hand, the mutations observed in Delta have overall less impact in affecting allele-specific HLA peptide binding affinity than those observed in Omicron. Supplementary Table 2 gives the prediction of the most significant interactions between specific HLA molecules and Spike proteins lost due to the mutations observed in Omicron and Delta. Numerous bioinformatic predictions for SARS-CoV-2 T cell epitopes have also been undertaken to narrow the search space for relevant epitopes [40] [41] [42] . Many of these efforts were designed and validated to predict dominant, promiscuous epitopes, independent of ancestry and HLA polymorphism [43] , identifying the most parsimonious set of 25-mers to cover the largest population [40] . These immunoinformatic approaches generally compare multiple SARS-CoV-2 sequences and use different algorithms to predict HLA affinity for epitopes from the 10 unique SARS-CoV-2 proteins.

Although in silico prediction is extremely useful for identifying antigenic peptides, several steps in the antigen presentation pathway may represent a limitation for this strategy. Examples are the protein degradation in the endosomal pathway, degradation of peptides by aminopeptidases in the cytosol, and translocation into the endoplasmic reticulum [44] , which are not always immunogenic and a subset of immunodominant SARS-CoV-2 T cell epitopes [46] . Another study applied peptide-loaded HLA tetramers to perform an ex-vivo analysis of pre-existing induced SARS-CoV-2-specific CD8+ T cells and identified a set of immunodominant peptides [47] .

Analyzing 31 patients with COVID-19, Gangaev et al. [48] analyzed peptide-HLA class I complexes restricted to 10 common HLA molecules and identified 18 recognized by CD8+ T cells. They further analyzed CD8 T responses and observed gene expression patterns of constrained T cell re-activation, in addition to high expression of the gene NKG2A and lack of J o u r n a l P r e -p r o o f cytokine production. More recently, mass spectrometry-based HLA-I immunopeptidomics revealed that SARS-CoV-2 peptides presented by HLA class I also derive from internal out-offrame open reading frames in spike and nucleocapsid not captured by current vaccines. In addition, this study has shown that early expressed SARS-CoV-2 proteins have a larger contribution to HLA-mediated immunogenicity [49] . Finally, it has been shown that immune response to SARS-CoV-2 is distinguished by HLA genotypes, in which the dominant immune response in HLA-B*07 was associated with a more diverse TCR repertoire compared to the response in HLA-A*02, HLA-A*24, and HLA-A*01 [50] .

Two years into the global pandemic, much has been learned about the relationship between HLA polymorphism, variation in SARS-CoV-2, and the impact that this variability has on antigen presentation and immunity. However, the rapid appearance of immune evasive strains has rendered a more complete understanding of these relationships something of a moving target.

Likewise, examination of more and diverse populations is needed to fully comprehend the role of HLA in disease outcomes and vaccine response and efficacy. In the future, additional largescale studies will be needed to more fully detail the finely tuned relationship of the HLA system and continually novel SARS-CoV-2 strains to improve our understanding of the impact of antigen presentation in disease.

This work was supported by the National Institutes of Health, USA (NIH grant R01AI159260). 

Clinical Characteristics of Covid-19 in

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection

A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2

The Cell Biology of Antigen Processing and Presentation

Epithelial MHC Class II Expression and Its Role in Antigen Presentation in the Gastrointestinal and Respiratory Tracts

The HLA genomic loci map: expression, interaction, diversity and disease

The IPD and IMGT/HLA database: allele variant databases

Zooming into the binding groove of HLA molecules: which positions and which substitutions change peptide binding most?

Excess of Deleterious Mutations around HLA Genes Reveals Evolutionary Cost of Balancing Selection

An immunogenetic view of COVID-19

Mapping the human genetic architecture of COVID-19

MHC Haplotyping of SARS-CoV-2 Patients: HLA Subtypes Are Not Associated with the Presence and Severity of COVID-19 in the Israeli Population

Increased risk of severe clinical course of COVID-19 in carriers of

This study identified a strong association of HLA-C*04:01 with severe outcome of COVID-19, showing that individuals carrying this allele had twice the risk of intubation after infection with SARS-CoV-2

Age and Sex Are Associated With Severity of Japanese COVID-19 With Respiratory Failure

Association of HLA-DRB1*09:01 with severe COVID-19

Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility

The influence of HLA genotype on the severity of COVID-19 infection

HLA-DRB1*04 may predict the severity of disease in a group of Iranian COVID-19 patients

HLA-B*15:01 is associated with asymptomatic SARS-CoV-2 infection

HLA genetic polymorphism in patients with Coronavirus Disease 2019 in Midwestern United States. Hla 2021

HLA-B*15 predicts survival in Egyptian patients with COVID-19

HLA alleles frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. Hla 2020

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

In silico identification of vaccine targets for 2019-nCoV

Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2

Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study

Association of HLA class I with severe acute respiratory syndrome coronavirus infection

Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action

COVID-19 vaccines

Veesler D: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination

NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data

T-CoV: a comprehensive portal of HLA-peptide interactions affected by SARS-CoV-2 mutations

), an online portal that allows users to comprehensively analyze how mutations in multiple SARS-CoV-2 strains are predicted to affect HLA peptide binding affinities

COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa

Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa

HLA Diversity in the 1000 Genomes Dataset

Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes

Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

This paper analyzed the homology of multiple coronaviruses to identify potential T and B cell epitopes for SARS-CoV-2, aiming to better understand antigen presentation facilitate vaccine design

Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes

Towards a systems understanding of MHC class I and MHC class II antigen presentation

Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients

Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells

This study analyzed epitopes that were predicted in silico to bind to HLA allotypes that are common in worldwide populations and confirmed T-cell responses to 62% of the predicted peptides

Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features

This study identified 18 SARS-CoV-2 epitopes recognized by CD8+ T cells and performed indepth characterization of SARS-CoV-2-specific CD8+ T cell responses of patients with acute critical and severe disease

Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs

This study describes the first HLA-class I immunopeptidome of SARS-CoV-2 in two cell lines at different times post infection using mass spectrometry

Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2

••Applying single-cell, multi-omic technology, this study characterized T-cell to SARS-CoV-2 across different HLA class I alleles, showing that HLA genotype influences CD8+ T cell repertoire shape and utilization of immune recall.J o u r n a l P r e -p r o o f 

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: